Evidence map›Paper›PMID 38881341›Full record

ArticleActa oncologica (Stockholm, Sweden)2024

Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences.

Erika Tóth, Zsófia Kürönya, Edina Soós, Tamás Pintér, Henriett Butz, Zsolt Horváth, Erzsébet Csernák, Vince Kornél Grolmusz, Judit Székely, Tamás Straussz and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Erika TóthNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest.
Zsófia KürönyaNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology.
Edina SoósNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology.
Tamás PintérNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology.
Henriett ButzNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Molecular Genetics, National Institute of Oncology; HUN-REN Hereditary Cancer Research Group, Budapest, Hungary; Central Biobank, National Institute of Oncology, Budapest.
Zsolt HorváthNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology.
Erzsébet CsernákNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest.
Vince Kornél GrolmuszNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Molecular Genetics, National Institute of Oncology; HUN-REN Hereditary Cancer Research Group, Budapest, Hungary.
Judit SzékelyNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Tamás StrausszNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest.
József LöveyNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Levenete JánváriNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
László Báthory-FülöpNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest.
Péter NagyNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary.
Csaba PolgárNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Attila PatócsNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; Department of Molecular Genetics, National Institute of Oncology; HUN-REN Hereditary Cancer Research Group, Budapest, Hungary. attilapatocsb@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent developments in molecular genetic testing methods (e.g. next-generation sequencing [NGS]-panels) largely accelerated the process of finding the most appropriate targeted therapeutic intervention for cancer patients based on molecularly targetable genetic alterations. In Hungary, a centralized approval system following the recommendation of the National Molecular Tumor Board was launched for the coordination of all aspects of comprehensive genetic profiling (CGP) including patient selection and therapy reimbursement.

aimThe study aims to evaluate the clinical benefit of CGP in our Comprehensive Cancer Center Methods and patients: CGP was introduced into our routine clinical practice in 2021. An NGS-based large (> 500 genes) gene panel was used for cases where molecular genetic testing was approved by the National Molecular Tumor Board. From 2021 until August 2023 163 cases were tested. The majority of them were ECOG 0-1 patients with advanced-stage diseases, histologically rare cancer, or cancers with unknown primary tumours.

resultsSeventy-four cases (74 of 163, 45%) had clinically relevant genetic alterations. In 34 patients, the identified variants represented an indication for an approved therapy (approved by the Hungarian authorities, on-label indication), while in 40 cases the recommended therapy did not have an approved indication in Hungary for certain tumour types, but off-label indication could be recommended. Based on our CGP results, 24 patients (24/163; 14.7%) received targeted therapy. Treatment duration was between 1 and 60 months. In total 14 (14/163; 8.5% of the tested cases) patients had a positive clinical response (objective response or stable disease) and were treated for more than 16 weeks.

interpretationNGS-based CGP was successfully introduced in our institution and a significant number of patients benefited from comprehensive genetic tests. Our preliminary results can serve as the starting point of Drug Rediscovery Protocol (DRUP) studies.

Indexed as

Genetic TestingHigh-Throughput Nucleotide SequencingNeoplasmsPrecision MedicineAdolescentAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansHungaryMaleMiddle AgedMolecular Targeted TherapyYoung AdultBiomarkers, Tumor

Identifiers

PMID38881341
PMCPMC11332519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.